0001104659-21-123185.txt : 20211005 0001104659-21-123185.hdr.sgml : 20211005 20211005170111 ACCESSION NUMBER: 0001104659-21-123185 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211001 FILED AS OF DATE: 20211005 DATE AS OF CHANGE: 20211005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Korbel Gregory Alan CENTRAL INDEX KEY: 0001789032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 211307535 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6095104718 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 tm2129205-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-10-01 0 0001781983 Aprea Therapeutics, Inc. APRE 0001789032 Korbel Gregory Alan 535 BOYLSTON STREET BOSTON MA 02116 0 1 0 0 SVP, Chief Business Officer Common Stock 2021-10-01 4 M 0 27500 0.92 A 44667 D Common Stock 2021-10-01 4 S 0 27500 4.89 D 17167 D Stock Option (right to Buy) 0.92 2021-10-01 4 M 0 27500 0 D 2026-09-14 Common Stock 27500 25245 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.06 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option was granted on September 14, 2016 and is fully exercisable. /s/ Scott M. Coiante, attorney-in-fact 2021-10-05